Comprehensive Medical Weight Loss Denver
Weight Loss Strategies for patients of Clinical Nutrition Center in Denver, CO.
Eight-five percent. That’s how many people stop taking their GLP-1 medication within two years. Not because the drugs stopped working. Not because they got lazy. Because the approach was wrong from the start. GLP-1 medications—Ozempic, Wegovy, Zepbound, Foundayo and their…
GLP-1 Medications and Cancer Risk: What a New Study Shows Published May 26, 2026 | Dr. Ethan Lazarus, MD A new study adds to a growing body of evidence that GLP-1 receptor agonists may do more than lower blood sugar…
A patient came in last month frustrated. She’d been on a GLP-1 medication for four months, had lost 18 pounds — and yet her body composition told a different story. She’d dropped muscle, not just fat. When I asked her…
For years, the standard answer was: eat less, move more. If that didn’t work, you didn’t try hard enough. We know better now. GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) work — in clinical trials, they work…
New Phase 3 Data: Survodutide Delivers 16.6% Weight Loss — Dual GLP-1/Glucagon Agonist Shows Metabolic Benefits Beyond the Scale The SYNCHRONIZE-1 Phase 3 trial results are in — and they’re worth your attention. Survodutide (BI 456906), Boehringer Ingelheim’s novel dual…
Amazon just entered the weight loss drug business. And if you’ve been watching the GLP-1 space, you probably saw it coming. On April 21, 2026, Amazon launched a GLP-1 Management Program through Amazon One Medical — combining virtual visits, prescription…
For years, the prevailing assumption was simple: GLP-1 drugs help the liver because they help you lose weight. Cut calories, shed pounds, your liver gets less fat, inflammation calms down. Thglp-1hanism seemed obvious. New research from Sinai Health in Toronto…
Not all GLP-1s are the same. And for the first time in this drug class, you actually have real choices. With orforglipron (Foundayo) now FDA-approved and oral Wegovy (25 mg semaglutide) newly available, patients and doctors face a genuinely useorforglipron:…
Let me start with a number that should get your attention: 28.7%. That’s how much body weight participants lost in the latest Phase 3 trial of retatrutide, Eli Lilly’s investigational triple-agonist obesity medication. At 68 weeks, the average weight loss…
You’ve typed “registered dietitian near me” into your phone at least three times this month. Maybe you finally got tired of guessing which diet actually works. Maybe your doctor suggested it. Or maybe you just want to talk to someone…
